3.2
Impact Factor

PDF

Int J Med Sci 2025; 22(13):3439-3453. doi:10.7150/ijms.114924 This issue Cite

Review

Effect of Pituitary-Target Gland Axis on RAAS in the Context of COVID-19

Baofeng Wu^1,2*, Ru Li^1,2*, Qinhao Liu^1,2, Shuqing Jin^1,2, Hongxia Wei^1,2, Ming Xu^1,2, Yi Zhang³ , Yunfeng Liu^1,4

1. Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China.
2. First Clinical Medical College, Shanxi Medical University, Taiyuan, 030001, China.
3. Department of Pharmacology, Shanxi Medical University, Taiyuan, 030001, China.
4. Clinical Research Center of Endocrine and Metabolic Disease in Shanxi Medical University, Taiyuan, 030001, China.
* These authors contributed equally to this work and share first authorship.

✉ Corresponding authors: Yunfeng Liu, email address: nectarliucom, Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China. Yi Zhang, email address: yizhang313com, Department of Pharmacology, Shanxi Medical University, Taiyuan, 030001, China. More

Received 2025-4-2; Accepted 2025-7-8; Published 2025-7-25

Abstract

The pituitary gland is a very important endocrine gland in the human body. It secretes and releases many hormones crucial for controlling physiological processes, such as energy metabolism, human growth and development, and reproduction. The renin-angiotensin-aldosterone system regulates water and salt homeostasis, controlling blood pressure. Since the discovery of the renin-angiotensin-aldosterone system, exploring and studying its role in pathophysiology has never stopped, and patients have benefited from drug-based and clinical studies. This review focuses on the effects of the pituitary-target gland axis (pituitary-thyroid axis, pituitary-adrenal axis, pituitary-growth hormone axis, pituitary-gonadal axis) and some hormones secreted and stored by the pituitary gland on the RAAS. While considering that SARS-CoV-2 reinfection still occurs, we aim to provide new insights into water-electrolyte balance and blood pressure regulation.

Keywords: Pituitary gland, Renin-angiotensin-aldosterone system, Pituitary hormones, COVID-19, SARS-CoV-2

Introduction

The endocrine system primarily consists of endocrine glands (including the pituitary, thyroid, parathyroid, adrenal, and gonads), as well as endocrine tissues and cells found in various organs, such as the cardiovascular, gastrointestinal, renal, adipose tissue, and brain (especially the hypothalamus). The endocrine system is an important regulatory system of the body, complementing the nervous system in maintaining the balance and stability of the internal environment. It regulates the growth and development of the body, as well as various metabolic activities, and influences various behaviors. The hypothalamus-pituitary-target gland axis plays a vital role in the homeostasis of hormone secretion. The pituitary gland is a grey-red oval-shaped body located in the pituitary fossa of the pterygoid saddle at the base of the skull, which can be divided into two major parts: the adenohypophysis and the neurohypophysis. The adenohypophysis secretes growth hormone (GH), thyroid-stimulating hormone (TSH), adrenocorticotropic hormone (ACTH), and gonadotropin, while the neurohypophysis stores and releases antidiuretic hormone (vasopressin) and oxytocin, synthesized by neuroendocrine cells in the supraoptic nucleus and paraventricular nucleus of the hypothalamus [1, 2]. The pituitary gland is the most important endocrine gland in the body, controlling the secretion of various hormones essential for metabolism, growth, development, and reproduction.

The renin-angiotensin-aldosterone system (RAAS) is vital in the body, maintaining plasma sodium concentration, arterial blood pressure, and extracellular fluid volume. Renin is a proteolytic enzyme synthesized, stored, and released by the juxtaglomerular cells that catalyzes the conversion of plasma angiotensinogen to angiotensin I (Ang I). Most of the renin is produced in the kidneys. Renin release is affected by the perfusion pressure of the glomerulus arteriole, the concentration of Na⁺ in the filtrate of the distal tubule flowing through the macula densa, and by renal sympathetic nerves [3, 4]. Ang I generates angiotensin II (Ang II) under the action of the angiotensin converting enzyme (ACE), which induces vasodilation by binding to the Ang II receptor 1 (AT1R). In the proximal convoluted tubules of the kidney, Ang II may increase Na⁺-H⁺ exchange, thereby increasing sodium reabsorption and raising arterial pressure in patients. Ang II also acts on the adrenocortical globular zone, which stimulates aldosterone release, thereby affecting sodium reabsorption and potassium excretion in the distal convoluted tubules and collecting ducts of the renal unit [5].

RAAS comprises the classical ACE/Ang II/AT1R axis and the non-classical ACE2/Ang(1-7)/Mas axis [6]. The ACE2/Ang(1-7)/Mas axis antagonizes the ACE/Ang II/AT1R axis, becoming the primary regulatory mode of the RAAS system [6, 7]. After SARS-CoV-2 infection, studies have found that ACE2, a receptor for SARS-CoV-2, mediates virus internalization and infection. However, SARS-CoV-2 binding to ACE2 downregulates ACE2 activity, leading to the accumulation of Ang II and excessive RAS activation [8, 9]. Elevated Ang II leads to vasoconstriction, inflammation, cell differentiation and growth, endothelial dysfunction, the production of reactive oxygen species, and microthrombosis (Figure 1). Circulating ACE2 is a biomarker of COVID-19 mortality [10]. A study following SARS-CoV-2 infection revealed that Ang II levels were higher in COVID-19 patients compared to controls, and a linear relationship existed between high Ang II levels and adverse clinical outcomes [11]. Hypertension may increase the risk of severe or fatal COVID-19 in patients by 2.5 times, especially in older patients [12]. Angiotensin-converting enzyme inhibitors (ACEIs)/ Angiotensin receptor blockers (ARBs) can help alleviate multi-organ damage caused by excessive activation of RAAS without aggravating SARS-CoV-2 infection and reduce all-cause mortality in hospitalized patients [13, 14].

 Figure 1 

The Renin-Angiotensin-Aldosterone-System and the influence of SARS-CoV-2 on it. RAAS comprises classic ACE/Ang II/AT1 axis and non-classic ACE2/Ang(1-7)/Mas axis. ACE/Ang II/AT1 exerts its physiological effects through ATIR on many organs, such as the heart, brain and kidney, while ACE2/Ang(1-7)/Mas exerts antioxidant and anti-fibrotic effects. ACE2 and TMPRSS2 can mediate the internalization and infection of SARS-CoV-2, and reduce the protective ACE2/Ang(1-7)/Mas components, resulting in an imbalance of RAAS balance. ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; AT1R, angiotensin II receptor type 1; AT2R, angiotensin II receptor type 2; MasR, Mas receptor; TMPRSS2, transmembrane protease serines 2.

RAAS plays a crucial role in maintaining water and electrolyte balance. Most previous studies have focused on the role of the RAAS in the occurrence and development of diseases, as well as its use as a target for drug treatment. In contrast, there have been few studies on the effect of endocrine-related factors on the RAAS. Secondly, considering endocrine glands such as the hypothalamus, pituitary, thyroid, adrenal, testes, and ovaries express ACE2[15], the long-term effects of SARS-CoV-2 infection on these organs and the RAAS are not very clear. Therefore, this article describes the effects of pituitary and target gland hormones on RAAS from the perspective of the pituitary-target gland axis and explores the possible mechanisms. At the same time, combined with the potential long-term effects of SARS-CoV-2 infection, it offers new insights into maintaining water and electrolyte balance and regulating blood pressure.

COVID-19 and the Pituitary gland

As mentioned earlier, ACE2 is expressed in various organs and tissues, allowing the infection to spread rapidly beyond the respiratory system to other organs. The SARS-CoV-2 virus may enter the brain through the blood-brain barrier via the nasopharyngeal epithelium or systemic vascular circulation [15]. Although ACE2 expression is low in the pituitary, SARS-CoV-2 has a strong binding ability with ACE2, which means that the pituitary is more susceptible to direct damage by the virus [16]. COVID-19 has been found to cause a variety of pituitary injuries, including pituitary apoplexy, hypophysitis, hypopituitarism, and arginine vasopressin deficiency [17-20]. For example, among post-infection hypophysitis caused by COVID-19, studies have found that cases of post-infection hypophysitis are relatively rare; however, the onset age of COVID-19-related hypophysitis is lower than that of other types, and the incidence is higher in pediatric patients, especially adolescents [21]. Interestingly, the most common pituitary disease after COVID-19 vaccination was hypophysitis. Secondly, due to the harmful effects of SARS-CoV-2 infection on the hypothalamus and pituitary gland, as well as the widespread use of high-dose corticosteroids for treatment, patients with COVID-19 may have an increased risk of long-term adrenal insufficiency and are more likely to experience long-term sequelae [22].

After SARS-CoV-2 infection, sequelae can last from one week to several months and may even persist for life; the World Health Organization (WHO) refers to these conditions as "Long COVID-19"[23]. SARS-CoV-2 is a neurotropic virus, and the central nervous system is also a common target of SARS-CoV-2. In COVID-19-related studies, compared to other central nervous system studies, less research has been conducted on the pituitary. Studies have found that insufficient secretion of adrenocorticotropic hormone and growth hormone may be related to the pathogenesis of the long-term syndrome associated with COVID-19[24]. These findings underscore the complexity of Long COVID-19 and emphasize the importance of investigating the endocrine system, particularly the pituitary gland, to comprehend and address COVID-19 complications. Focusing on and addressing the hormonal disorders in patients with Long COVID-19 may provide a new way for the management and care of the disease.

Pituitary-thyroid axis and RAAS

Thyrotropin-releasing hormone (TRH) secreted by the hypothalamus stimulates the secretion of thyroid-stimulating hormone (TSH) by the anterior pituitary, which initiates the synthesis of thyroid hormone (TH) and its release from the thyroid gland through the TSH receptor (TSHR). TSHR belongs to the G protein-coupled receptor family, and its main expression site is the basolateral membrane of thyroid cells. TSHR is also expressed in the kidney and adrenal glands [25]. TH plays a vital role in the growth and development of various tissues, including the kidneys. The kidney is involved in the metabolism and elimination of TH, and renal insufficiency produces various changes in the metabolism of TH and upstream hormones, such as an increased basal TSH value, alterations in the TSH circadian rhythm, and impaired renal clearance of TSH [26]. The kidney is the site of renin release and angiotensin synthesis, and thyroid dysfunction may lead to abnormal RAAS function [27, 28].

Thyroid hormones influence the synthesis of angiotensinogen and other RAS components and ACE activity, and abnormal secretion of thyroid hormones can affect blood pressure. Hypothyroidism can manifest as decreased cardiac output and blood pressure, which is associated with a low plasma renin concentration and activity. This is because hypothyroidism renders the kidneys less sensitive to β-adrenergic stimulation, resulting in reduced renin gene expression and release, and ultimately, reduced RAAS activity [29]. Hyperthyroidism leads to the overexpression of ACE2 and causes RAAS dysregulation [31], manifested by hyperdynamic circulation and elevated blood pressure, which may be associated with an increased density and activity of β-adrenergic receptors in the renal cortex. Plasma renin activity, angiotensinogen, and aldosterone levels are directly related to thyroid hormone concentration [27, 30], which regulates water and electrolyte balance through its influence on RAAS components. Several animal experiments have found that hypothyroidism increases urine volume and sodium excretion, and affects the kidneys' ability to concentrate urine, whereas hyperthyroidism tends to retain sodium [31, 32].

The expression of ACE2 in the thyroid gland has been demonstrated, and the transmembrane protease serine 2 (TMPRSS2) is also highly expressed in the thyroid, regardless of gender differences [33]. David Tak Wai Lui et al. found that approximately 15% of patients with mild to moderate COVID-19 had thyroid dysfunction [34]. This means that after COVID-19 infection, the thyroid gland is vulnerable to damage and dysfunction. Subclinical hypothyroidism is the most common in COVID-19-infected patients. In addition to the impact on the RAAS system, these patients are also more likely to develop complications such as infection. Although the improvement of subclinical hypothyroidism may help reduce complications, the effect on electrolytes remains to be elucidated. Studies have found that T3 can reduce the number of SARS-CoV-2 binding sites on the surface of target cells compared with free thyroxine (FT4) [36]. However, the systemic administration of L-T3 remains controversial, and we expect to find more positive studies in the future. Most studies on COVID-19 and thyroid dysfunction have been retrospective, which makes it challenging to observe the dynamic evolution of thyroid function during COVID-19 or correlate its impact on the RAAS. The results of more prospective studies are expected to explore the effects of SARS-CoV-2 on RAAS in the pituitary-thyroid axis.

Pituitary-adrenal axis and RAAS

The hypothalamic-pituitary-adrenal axis (HPA axis) is an important neuroendocrine system that mediates stress and stress-related responses, and cortisol is the primary hormone produced by the HPA axis. Under stress induction, corticotropin releasing hormone (CRH) secreted by the hypothalamus activates the pituitary gland. Then the pituitary gland releases the ACTH into the circulation (Figure 2). Cortisol can increase Ang II signaling in VSMC through glucocorticoid receptor-α (GRα). Ang II stimulates cortisol signaling by increasing GRα and 11β-hydroxysteroid dehydrogenase 1(11β-HSD1), and the interaction between them is conducive to the development of atherosclerosis [35]. The HPA axis and RAAS are associated with increased blood pressure. A study on the Japanese population revealed that the HPA axis has a significant effect on blood pressure than the RAAS [36]. Under pathological conditions, such as in patients with Cushing's syndrome, excess cortisol increases renal blood flow and sodium reabsorption in the renal tubules. Cortisol can activate Na⁺/H⁺ exchanger 3 (NHE3) in the proximal tubule [37], Na⁺-K⁺-Cl^- cotransporter 2 (NKCC2) in the thick ascending limb of the loop [38], Na⁺-Cl^- cotransporter (NCC) in the distal convolve tubule, and epithelial sodium channels (ENaC) in the collecting duct [37]. In addition, cortisol can also increase the activity of the basolateral Na⁺-K⁺-ATPase [39]. Excess cortisol inhibits cortisol inactivation by 11β-hydroxysteroid dehydrogenase 2(11β-HSD2), activating mineralocorticoid receptors (MR) and subsequently activating NCC and ENaC. These changes increase the kidneys' reabsorption of sodium and water, thus raising blood pressure. The physiological effects of cortisol on blood pressure and electrolytes may also be related to these changes.

ACTH stimulates the adrenal cortex to promote the production of cortisol in the zona fasciculata and aldosterone in the zona glomerulosa [40]. ACTH binds to the melanocortin 2 receptor (MC2R) and causes stimulated adenylate cyclase to convert ATP to cyclic adenosine monophosphate(cAMP), increasing cAMP levels and stimulating protein kinase A (PKA). PKAs increase calcium influx to increase intracellular calcium levels and activate calmodulin-dependent protein kinase (CaMK). PKA and CaMK phosphorylate and activate ATF/CREB transcription factors to induce steroidogenic acute regulatory protein (StAR) and aldosterone synthase gene (CYP11B2) expression, which are early and late rate-limiting steps in aldosterone biosynthesis (Figure 3) [41]. Aldosterone is produced primarily in the zone glomerulosa of the adrenal glands and regulates sodium and potassium balance and blood pressure by binding to MR in the kidneys. It is mainly regulated by plasma potassium and RAAS; other acute regulators include ACTH and serotonin. However, ACTH can only stimulate aldosterone secretion acutely and temporarily, to a much lower degree than the RAAS and plasma potassium [42]. Aldosterone is highly responsive to the infusion of physiological doses of ACTH. The responsiveness of renin to ACTH infusion remains uncertain, with renin levels found to be either unaltered by ACTH stimulation or to exhibit delayed elevation several hours after ACTH infusion [43]. However, a recent study found that increased ACTH during the stressful state was associated with higher aldosterone and renin responsiveness in acute stress-induced RAAS-related changes [44].

Both the HPA axis and RAAS play an indispensable role in the body. ACTH mainly promotes the secretion of cortisol, which mainly binds to the glucocorticoid receptor (GR), but also binds to MR. The effect of this mineralocorticoidal effect of cortisol on RAAS is often ignored. Both glucocorticoids (cortisol) and mineralocorticoids (aldosterone) regulate blood pressure and are present in disorders such as Cushing's syndrome and primary aldosteronism to contribute to hypertension. When adrenal insufficiency occurs after SARS-CoV-2 infection, it is difficult to say whether it is due to viral infection or glucocorticoid treatment. Although it has been confirmed that ACE2 and TMPRSS2 are co-localized in adrenocortical cells [45], there is currently no evidence that adrenocortical function is continuously affected [46]. However, TMPRSS2 expression can be detected in the adrenal zona glomerulosa, which means that aldosterone secretion can also be affected, but little attention has been paid to the effect of SARS-CoV-2 infection on adrenocortical hormones. The HPA axis is the most studied in Long COVID syndromes, with some studies reporting that long-term impairment leads to mild and subclinical forms of central adrenal insufficiency [47]. However, there is a lack of studies on the interaction between the HPA axis and RAAS in blood pressure, electrolyte regulation, and lipid metabolism, and even less on the crosstalk between the two systems after SARS-CoV-2 infection. We hope this review will inspire new ideas about these two systems.

 Figure 2 

HPA axis and RAAS. ACTH plays a significant role in the HPA axis, promoting cortisol secretion and affecting blood pressure and RAAS. ACTH can also stimulate aldosterone secretion acutely and briefly, but this stimulation is minimal under physiological conditions.

Pituitary-gonadal axis and RAAS

The hypothalamus produces gonadotropin-releasing hormone (GnRH), which acts on anterior pituitary gonadotrophs through the pituitary portal circulation to produce follicle stimulating hormone (FSH) and luteinizing hormone (LH). FSH mediates various biological effects through the FSH receptor (FSHR). Zhen Yu et al. found that FSH could promote renin production through FSHR expressed in juxtaglomerular cells, triggering the MEK/Erk and Akt signaling pathways via Gsα activation [48]. LH is involved in the maturation of primordial germ cells in both sexes. LH exerts related physiological effects by binding to LH receptors, which are mainly expressed in gonadal cells. LH can promote the synthesis of prorenin in the corpus luteum. Studies have shown a direct relationship between the number of corpus luteum and the level of renin [49]. However, few studies have shown the direct effects of FSH and LH on RAAS. Therefore, this part will analyze the effects of estrogen, progesterone, and androgen on RAAS from the perspective of the pituitary-gonadal axis.

Estrogen

Estrogen is a steroid hormone associated with the female reproductive organs and is responsible for developing female sexual characteristics. Estrogen is usually divided into estrone, estradiol, and estriol. Estradiol, also known as 17-β-estradiol, is the most abundant form of estrogen in the human body, and the other two natural forms are present in lower amounts [50]. A woman's circulating estrogen level fluctuates monthly and decreases during pregnancy and after menopause. Estrogen is a vasodilator, and normal estrogen levels can antagonize the RAAS by down-regulating the level of ACE and increasing the release of bradykinin, which prevents vasoconstriction and hypertension by promoting vasodilation and inducing the production of protective nitric oxide [51].

 Figure 3 

ACTH mediates the secretion of cortisol and aldosterone. ACTH binds to MC2R, a G-protein coupled receptor coupled with the Gsα subunit. It can increase intracellular cAMP concentration, thus activating PKA, phosphorylating CREB and ATF1, increasing the transcription of CYP11B2 and CYP11B1, and generating aldosterone and cortisol, respectively. ACTH, adrenocorticotropic hormone; MC2R, melanocortin 2 receptor; Gsα, Gs protein alpha subunit; AC, adenylate cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; CREB, cAMP response element binding protein; ATF1, activating transcription factor 1; P, phosphorylation.

Estrogen can bind to estrogen receptors (ERα and ERβ) in endothelial and vascular smooth muscle cells, increasing NO bioavailability and promoting vasodilation. For example, 17β-estradiol can delay the aging of vascular endothelial cells (VECs) by acting on ERα [52]. ERβ can mediate vascular relaxation, and the deficiency of this receptor can lead to vascular dysfunction and hypertension [53]. The adrenal cortex expresses all estrogen receptor subtypes, with the highest expression of ERβ in the zona glomerulosa. In premenopausal women, high estrogen levels may inhibit aldosterone synthesis through ERβ, which could explain why estrogen hormone replacement therapy reduces blood pressure in postmenopausal women (Figure 4). After menopause, the antihypertensive effect of estrogen-mediated by ERβ disappears. In contrast, the release of aldosterone mediated by G protein-coupled estrogen receptor 1(GPER1) promotes increased blood pressure, partly explaining the high prevalence of resistant hypertension in postmenopausal women [54]. Overactivation of RAAS has been implicated in the pathogenesis of hypertension, and both endogenous and exogenous estrogens alter the balance between vasoconstriction and relaxation of RAAS.

There are gender differences in RAAS. The expression level of ACE/Ang-II/AT1R axis is higher in males, while ACE2/Ang(1-7)/Mas is more active in females, which means that RAAS in males is more susceptible to SARS-CoV-2 and has a higher risk of serious complications and death after illness [55]. The down-regulation of ACE2 by SARS-CoV-2 leads to increased Ang II, which in turn causes vasoconstriction, hypertension, and inflammation. 17β-estradiol can enhance the expression of ACE2 (ACE2/Mas axis) and reduce ARDS by controlling RAAS [56]. Estrogen may also exert a greater protective effect on the vasculature by activating endothelial nitric oxide synthase (eNOS) and stimulating NO and cyclic guanosine monophosphate (cGMP). COVID-19 severity was reduced in postmenopausal women who received supplemental estrogen compared to age-matched women and men who did not take estrogen [57]. The potential protective effect of estradiol was further illustrated by the study by Ute Seeland et al., which found that women receiving treatment containing estradiol had a 50% lower risk of death after SARS-CoV-2 infection compared with premenopausal women not receiving hormone replacement therapy (HRT) [58]. 17β-estradiol levels decline with age in postmenopausal women, making women more susceptible to RAAS-related conditions such as ARDS and other acute lung injury diseases, hypertension, and cardiovascular disease. Estrogen therapy may provide a new direction for the treatment of SARS-CoV-2 infection.

 Figure 4 

Estrogen-mediated aldosterone production in the adrenocortical zona. Estrogen mediates vascular endothelial cell relaxation by acting on ERα and ERβ. Estrogen dimerizes with ERβ and binds to ERE in the nucleus, inhibiting the transcription of CYP11B2, thereby reducing aldosterone synthesis. GPER1 induces the expression of aldosterone synthase through the AC/PKA signaling pathway, which ERβ-mediated effects can physiologically inhibit. E, estrogen; ERα, estrogen receptor type α; ERβ, estrogen receptor type β; GPER1, G protein-coupled estrogen receptor type 1; eNOS, nitric oxide synthase; NO, nitric oxide;cGMP, cyclic guanosine monophosphate; ERE, estrogen response element; AC, adenylate cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A.

Progesterone

Progesterone is an endogenous steroid hormone typically produced by the adrenal cortex, ovaries, and testes, and its primary role is maintaining pregnancy. Progesterone has a neutral or inhibitory effect on blood pressure [59], and the decrease in blood pressure is positively correlated with the increase in progesterone as pregnancy progresses [60]. Several studies have found that similar to estradiol, progesterone induces endothelium-dependent vasodilation [61].

Progesterone has the potential to affect aldosterone production through several mechanisms. Progesterone is a competitive inhibitor of MRs, and progestin-induced urinary sodium excretion may lead to compensatory activation of the RAS in the luteal phase [62, 63]. Secondary progestin-induced vasodilation could also lead to RAS activation [64], and PRA and AngII would be expected to increase in parallel with aldosterone levels if this were the primary mechanism at work. However, in actual clinical studies, exogenous administration of progesterone did not find an increase in plasma renin activity and AngII [65-67]. Emily D Szmuilowicz et al. added progesterone to isolated rat adrenal zona glomerulosa cells, resulting in a 2.8-fold increase in aldosterone production. In contrast, the addition of estradiol had no effect. Suggesting that progesterone may directly affect adrenal aldosterone production, which may also be a potential mechanism for increased aldosterone production in a physiological state of high progesterone [67].

There is some evidence that progesterone may also show sex differences in the treatment of SARS-CoV-2 infection, and Ghandehari et al. [68] used progesterone (100 mg, subcutaneously, twice a day, for up to 5 days) in a randomized controlled trial to treat hospitalized male patients with moderate to severe COVID-19 and found improvement in hypoxemia in male hospitalized patients. Electrolyte disturbances secondary to SARS-CoV-2 infection are common [69], and Elabida et al. have provided strong evidence for the important role of progesterone in regulating electrolyte balance [70]. Estrogen and progestin as complementary therapy after SARS-CoV-2 infection is currently being evaluated in multiple studies [71], and exciting trial results are expected.

Androgen

Androgens are endocrine hormones that maintain reproduction and metabolism. Testosterone and its active metabolite dihydrotestosterone (DHT) are the major androgens in the circulation of mature male mammals. "Classical androgen signaling" refers to the genomic effects mediated by the androgen receptor (AR) in the cytoplasm [72]. Testosterone and DHT are ligands for AR. Testosterone increases renin levels, ACE, and AT1R expression, while down-regulating AT2R expression, leading to vasoconstriction [73, 74]. Androgen has been found to enhance vascular responsiveness to Ang II in hypertensive rats [75]. By studying the relationship between testosterone and blood pressure, Tina Kienitz et al. [76] found that androgen signaling stimulates Na⁺ reabsorption in the kidney's proximal tubule, which may be related to the up-regulation of intrarenal Ang II. Secondly, the interaction between testosterone and ARs, up-regulating αENaC expression by serum/glucocorticoid regulated kinase 1 (SGK1) and blocking the endocytosis of ENaC mediated by Nedd4-2 phosphorylation, may be important in developing hypertension. In a mouse model of polycystic ovary syndrome, long-term chronic administration of DHT increased angiotensinogen mRNA expression by 9-fold and ACE mRNA by approximately 0.5-fold [77]. Numerous studies have shown [78, 79] that testosterone may shift the balance of RAS toward Ang II-ACE-AT1R pathway to induce vasoconstriction, vascular dysfunction, and elevated blood pressure (Figure 5).

 Figure 5 

Effects of androgen and SARS-CoV-2 on RAAS. Androgens increase blood pressure by affecting RAAS-related components, and ACE2-mediated SARS-CoV-2 infection causes acute kidney damage. The red line represents inhibition, the green line represents facilitation, and the black line represents downstream influence. ACE, angiotensin-converting enzyme; ACE2, angiotensin-converting enzyme 2; AT1R, angiotensin II receptor type 1; AT2R, angiotensin II receptor type 2; AngII, angiotensin II.

SARS-CoV-2 enters cells by binding to ACE2 and TMPRSS2, which is also expressed in adult Leydig cells [80], so infection with SARS-CoV-2 may alter the ability of the testis to produce or secrete androgens [81]. Testosterone may act as a double-edged sword in the SARS-CoV-2 pandemic. On the one hand, androgens can affect the immune response by increasing cytokine production and decreasing antibody responses to infectious diseases, which can lead to severe infections in men [82]. On the other hand, some studies have found that in elderly men, lower testosterone levels reduce immunosuppression, making them more likely to develop a solid immune inflammatory response, and the degree of testosterone reduction is a predictor of disease severity after SARS-CoV-2 infection [83, 84]. This indicates that androgens can be used as adjuvant therapy in patients with COVID-19, as an earlier study demonstrates [85]. However, the severity of lung involvement during COVID-19 infection is associated with androgen excess [86]. Indeed, androgen-modulating drugs have been proposed as potential treatments for COVID-19[87], and prostate cancer patients receiving antiandrogen therapy appear to be partially protected from SARS-CoV-2 infection [88]. The short- or long-term effects of SARS-CoV-2 infection are still unclear, and the role of low and high levels of testosterone remains controversial [90]. Therefore, we look forward to more comprehensive studies to explore the role of SARS-CoV-2 infection in testosterone and blood pressure.

Summary

The pituitary-gonadal axis affects RAAS by affecting the secretion of various sex hormones, thereby regulating the water and sodium balance. It suggests that we should not ignore the changes and potential role of gonadal hormones in the disease's cognition and related hormone replacement therapy. Some studies have found that SARS-CoV-2 infection impacts the HPG axis. The current evidence has only partially explained the role of sex hormones in COVID-19. The use of hormone replacement or suppression therapy is still controversial, and different sex hormone therapy has different benefits and risks after SARS-CoV-2 infection (Table 1). However, the long-term follow-up data on the level of sex-related hormones before and after SARS-CoV-2 infection is not perfect, and the potential impact on the HPG axis cannot be analyzed comprehensively.

Pituitary-growth hormone axis and RAAS

Growth hormone (GH) is a protein secreted by growth hormone cells in the anterior pituitary gland. Its primary function is to promote the growth and development of children and adolescents, but it also plays other vital roles in whole-life activities, such as affecting the metabolism of glucose, fats, and proteins. Other potential effects, such as those on fibrosis, cardiovascular function, and cancer, are also being recognized [89, 90]. GH produces a direct or indirect effect, the direct effect is achieved by binding to GH receptor (GHR) on target cells, and the indirect effect is that GH acts on the liver to stimulate the synthesis and secretion of insulin-like growth factor-1 (IGF-1), and then affects the growth and metabolism of surrounding tissues [91].

The effects of GH are mediated mainly by GH-induced growth factors, among which IGF-1 has been the most widely studied in physiology [90], and GH/IGF-1 has long been considered an essential regulatory system for renal tubular sodium and water reabsorption [92]. GH deficiency is associated with lower sodium and water levels in the body, which can be ameliorated by rhGH replacement therapy [93]. Conversely, excessive GH in the body or treatment with high doses of rhGH may even lead to acute fluid retention [94]. Recent studies find the pituitary-growth hormone axis for sodium and water reabsorption in renal tubules via IGF-1, considering that both GH and IGF-1 receptors are expressed throughout the nephron, the site of GH/IGF-1 regulation of sodium reabsorption has been controversial. One of the most apparent effects of GH and IGF-1 on the kidney is their role in sodium retention in the distal tubule [95]. In cortical collecting duct cells, GH binding to GHR triggers activation of the JAK2/STAT5 and MAPK pathways. This results in transcriptional activation of kidney-specific GH target genes, including αENaC. IGF-1, locally synthesized in the kidney or obtained from the peripheral circulation, binds to IGF-1R and is activated by phosphatidylinositol 3-kinase (PI3K) -dependent SGK1, whose phosphorylation inhibits the ubiquitin ligase Nedd4-2, thereby regulating the expression of ENaC on the cell membrane surface [96]. These two mechanisms synergistically promote sodium reabsorption in the collecting ducts (Figure 6) [97].

Our previous study suggested that GH/IGF-1 could regulate the components of RAAS, promote sodium and water reabsorption, induce the increase of extracellular fluid, and even contribute to hypertension. Overexpression of GH can inhibit the ACE2/Ang-(1-7)/Mas axis, a finding confirmed in relevant animal experiments [98, 99]. Interestingly, following SARS-CoV-2 infection, several studies have found a possible association between low IGF-1 levels (and possibly GH) and poor outcomes in patients with COVID-19 [101, 102], while a lower rate of positive SARS-CoV-2 infection was observed in children receiving GH replacement therapy [100]. It seems to be somewhat contradictory to our current knowledge, as some studies have found that high expression of IGF-1 reduces COVID-19 susceptibility as well as poor prognosis [101, 102], but the resulting changes in blood pressure have not been studied in great intensity because hypertension is a risk factor for COVID-19 disease [103]. GH replacement therapy has played a positive role in children with SARS-CoV-2 infection, but it has side effects such as fluid retention, peripheral edema, arthralgia, and the risk of cancer in adults, especially elderly patients [104]. It suggests that we need to better understand the effects of GH/IGF-1 on RAAS under physiological and pathological conditions and the cascade of effects, which will help us understand the role of GH/IGF-1 in COVID-19.

 Figure 6 

Role of GH/IGF-1, aldosterone, and cortisol in renal collecting ducts. GH binding to GHR triggers activation of the STAT5 pathway, leading to transcriptional activation of GH target genes and increased expression of ENaC. IGF-1 can be synthesized locally or captured from the circulation, bound to IGF-1R, and activated via PI3K-dependent SGK1. SGK1, phosphorylating Nedd4/2, can inhibit its transport and degradation of ENaC. These two hormones act in concert and together regulate epithelial sodium transport. Aldosterone regulates ENaC by forming a dimer with MR to enter the nucleus and promote the expression of SGK1 and ENaC. The mineralocorticoid effect of cortisol is affected by 11β-HSD2, which converts cortisol to an inactive form and protects MR from activation by cortisol. Red lines indicate inhibition by phosphorylation or ubiquitination, and black lines indicate material movement or change to a phosphorylated state. GH, growth hormone; GHR, growth hormone receptor; IGF-1, insulin-like growth factor 1; IGF-1R, insulin-like growth factor 1 receptor; STAT5,signal transducer and activator of transcription 5; PI3K, phosphoinositide 3-kinase; SGK1, serum/Glucocorticoid regulated kinase 1; Nedd4-2, neural precursor cell expressed, developmentally down-regulated 4-2; ENaC, epithelial Na+ channel; A, aldosterone; C, cortisol; MR, mineralocorticoid receptor; 11β-HSD2, 11β-hydroxysteroid dehydrogenase 2; P, phosphorylated.

Arginine vasopressin (AVP) and RAAS

Antidiuretic hormone (ADH) or arginine vasopressin (AVP) is a nonapeptide synthesized in the supraoptic nucleus (SON) and paraventricular nucleus (PVN) of the hypothalamus and stored in the posterior pituitary gland. It is vital in regulating blood pressure, maintaining water and sodium balance, and maintaining renal function [105]. There are three distinct vasopressin receptor (VR) subtypes, V1aR, V1bR, and V2R. V1aR is mainly expressed in vascular smooth muscle to cause vasoconstriction. It also mediates cell proliferation, platelet aggregation, glycogenolysis, and lipid metabolism [106, 107]. V1bR is expressed in anterior pituitary cells and mainly stimulates the release of ACTH [108]. V2R mainly exists in the thick ascending limbs of Henle's loop (TAL) and collecting duct and promotes the expression of aquaporin 2 (AQP2) to increase water reabsorption [109].

In this part, we mainly discussed the functional crosstalk between AVP and RAAS and the influence of AVPs on water and sodium balance. It was found that AVP had specific effects on RAAS by increasing ENaC activity and binding with V1aR expressed by macula densa cells. ENaC is expressed in the apical cell membrane of aldosterone-sensitive distal nephritis (ASDN) [110], and aldosterone stimulates ENaC in ASDN via MR to minimize renal sodium excretion. V1aR has also been detected in the juxtaglomerular apparatus, the thick ascending limbs of Henle's loop, and collecting ducts of the kidney [111, 112]. AVP may also bind to V1aR in macula densa cells, inducing renin secretion, triggering RAAS activity, and indirectly increasing sodium reabsorption [113, 114]. Toshinori Aoyagi et al. demonstrated the effect of AVP/V1aR on renin secretion. They found that renin and Ang II were reduced in V1aR-deficient (V1aR^-/-) mice. It was also found that the expression of neuronal nitric oxide synthase and cyclooxygenase-2 was decreased in V1aR-specific macula densa cells, suggesting that AVP regulates the V2R-AQP2 system and glomerular filtration rate by stimulating the V1aR in the glomerular macula densa cells and thereby activating RAAS [114]. Secondly, Alexis A. Gonzalez et al. showed that V2R activation in mouse renal collecting duct cell lines (M-1 cell cultures) increased renin synthesis and secretion, and the V2R antagonist tolvaptan could block this effect and further demonstrated that the V2R-PKA- CREB signaling pathway in collecting duct renin production, which is independent of Ang II/AT1R (Figure 7) [115].

SARS-CoV-2 infection induces ACE2 downregulation, reducing vasodilator and protective Ang 1-7 and accumulating Ang II. Elevated Ang II stimulates the release of AVPs in the hypothalamus, leading to hyponatremia and the release of inflammatory cytokines [116]. Secondly, activated immune cells (mainly T and B lymphocytes) and the release of proinflammatory cytokines stimulate immune cells to release stored AVP, and this vicious cycle further triggers the release of proinflammatory cytokines [117]. Acute injury caused by SARS-CoV-2 infection induces the non-osmotic release of AVPs, leading to the syndrome of inappropriate antidiuresis (SIADH) and increased release of AVPs [118]. Many studies have shown that hyponatremia is associated with complications and mortality in COVID-19 patients [119, 120], and AVP receptor antagonists (VRAs) have also been shown to be a potential treatment for COVID-19 by alleviating AVP-mediated hyponatremia [121].

 Figure 7 

The regulation of renin in the macula densa and collecting ducts. AVP can bind to the V1aR of macula densa cells and the V2R of principal cells. AVP/V1aR stimulates the expression of nNOS and COX-2, leading to NO and PGE2 production by macula densa cells, which stimulates renin production by juxtaglomerular cells and subsequently induces an increase in Ang II and aldosterone levels to promote water reabsorption. AVP/V2R promotes renin gene expression by enhancing CREB phosphorylation through the cAMP/PKA pathway, and PKA also reduces ENaC degradation by phosphorylating Nedd4-2. AVP, arginine vasopressin; nNOS, neuronal nitric oxide synthase; COX-2, cyclooxygenase-2; NO, nitric oxide; PGE2, prostaglandin E2; AGT, angiotensinogen; Ang I, angiotensin I; Ang II, angiotensin II; ACE, angiotensin-converting enzyme; AC, adenylate cyclase; ATP, adenosine triphosphate; cAMP, cyclic adenosine monophosphate; PKA, protein kinase A; CREB, cAMP response element binding protein; V1aR, vasopressin receptor type 1a; V2R, vasopressin receptor type 2; AT1R, angiotensin II receptor type 1; ENaC, epithelial Na+ channel; Nedd4-2, neural precursor cell expressed, developmentally down-regulated 4-2; P, phosphorylated.

Conclusion

Hormones produced by the pituitary gland, such as TSH, ACTH, LH/FSH, GH, and AVP, affect the balance of RAAS through their direct or indirect effects. In endocrine diseases and many diseases involving water and sodium regulation and blood volume change, we should think about the clinical manifestations and treatment of diseases from more directions in order to obtain greater clinical benefits. In the post-pandemic era, the effects of SARS-CoV-2 have not entirely dissipated, and we should conduct long-term follow-up, observation, and research on the adverse effects of SARS-CoV-2 infection.

Acknowledgements

Funding

This work was supported by the Shanxi Provincial Central Leading Local Science and Technology Development Fund Project (YDZJSX20231A059, YDZJSX2022A059), the Four “Batches” Innovation Project of Invigorating Medical through Science and Technology of Shanxi Province (2023XM022), the Shanxi Province Higher Education “Billion Project” Science and Technology Guidance Project (BYJL-024).

Competing Interests

The authors have declared that no competing interest exists.

References

1. Alatzoglou KS, Gregory LC, Dattani MT. Development of the Pituitary Gland. Compr Physiol. 2020;10:389-413

2. Gounden V, Rampursat YD, Jialal I. Secretory tumors of the pituitary gland: a clinical biochemistry perspective. Clin Chem Lab Med. 2018;57:150-64

3. Kurtz A. Renin release: sites, mechanisms, and control. Annu Rev Physiol. 2011;73:377-99

4. Burlando B, Blanchini F, Giordano G. Loop analysis of blood pressure/volume homeostasis. PLoS Comput Biol. 2019;15:e1007346

5. Gilani M, Asif N, Akram A, Gilani M, Ijaz A, Malik SS. Spectrum of renin angiotensin aldosterone system disorders in young hypertensives. J Pak Med Assoc. 2018;68:1179-82

6. Santos RAS, Oudit GY, Verano-Braga T, Canta G, Steckelings UM, Bader M. The renin-angiotensin system: going beyond the classical paradigms. Am J Physiol Heart Circ Physiol. 2019;316:H958-H70

7. Guignabert C, de Man F, Lombès M. ACE2 as therapy for pulmonary arterial hypertension: the good outweighs the bad. Eur Respir J. 2018;51:1800848

8. Maranduca MA, Tanase DM, Cozma CT, Dima N, Clim A, Pinzariu AC. et al. The Impact of Angiotensin-Converting Enzyme-2/Angiotensin 1-7 Axis in Establishing Severe COVID-19 Consequences. Pharmaceutics. 2022;14:1906

9. Sodhi PV, Sidime F, Tarazona DD, Valdivia F, Levano KS. A Closer Look at ACE2 Signaling Pathway and Processing during COVID-19 Infection: Identifying Possible Targets. Vaccines (Basel). 2022;11:13

10. Fagyas M, Bánhegyi V, Úri K, Enyedi A, Lizanecz E, Mányiné IS. et al. Changes in the SARS-CoV-2 cellular receptor ACE2 levels in cardiovascular patients: a potential biomarker for the stratification of COVID-19 patients. Geroscience. 2021;43:2289-304

11. Wu Z, Hu R, Zhang C, Ren W, Yu A, Zhou X. Elevation of plasma angiotensin II level is a potential pathogenesis for the critically ill COVID-19 patients. Crit Care. 2020;24:290

12. Lippi G, Wong J, Henry BM. Hypertension in patients with coronavirus disease 2019 (COVID-19): a pooled analysis. Pol Arch Intern Med. 2020;130:304-9

13. Zhang P, Zhu L, Cai J, Lei F, Qin J-J, Xie J. et al. Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers with Mortality Among Patients with Hypertension Hospitalized With COVID-19. Circ Res. 2020;126:1671-81

14. Baral R, Tsampasian V, Debski M, Moran B, Garg P, Clark A. et al. Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4:e213594

15. Capatina C, Poiana C, Fleseriu M. Pituitary and SARS CoV-2: An unremitting conundrum. Best Pract Res Clin Endocrinol Metab. 2023;37:101752

16. Hoffmann M, Kleine-Weber H, Schroeder S, Krüger N, Herrler T, Erichsen S. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020;181:271-280.e8

17. Hazzi C, Villemure-Poliquin N, Nadeau S, Champagne P-O. SARS-CoV-2 Infection, A Risk Factor for Pituitary Apoplexy? A Case Series and Literature Review. Ear Nose Throat J. 2024;103:153S-61S

18. Khidir RJY, Ibrahim BAY, Adam MHM, Hassan RME, Fedail ASS, Abdulhamid RO. et al. Prevalence and outcomes of hyponatremia among COVID-19 patients: A systematic review and meta-analysis. Int J Health Sci (Qassim). 2022;16:69-84

19. Steenblock C, Toepfner N, Beuschlein F, Perakakis N, Mohan Anjana R, Mohan V. et al. SARS-CoV-2 infection and its effects on the endocrine system. Best Pract Res Clin Endocrinol Metab. 2023;37:101761

20. Carosi G, Cremaschi A, Giavoli C, Ferrante E, Mantovani G. Hypopituitarism and COVID-19. Pituitary. 2024;27:925-34

21. Menotti S, di Filippo L, Terenzi U, Chiloiro S, De Marinis L. Hypophysitis in COVID-19: a systematic review. Pituitary. 2024;27:874-88

22. di Filippo L, Franzese V, Santoro S, Doga M, Giustina A. Long COVID and pituitary dysfunctions: a bidirectional relationship? Pituitary. 2024;27:955-69

23. Carvajal JJ, García-Castillo V, Cuellar SV, Campillay-Véliz CP, Salazar-Ardiles C, Avellaneda AM. et al. New insights into the pathogenesis of SARS-CoV-2 during and after the COVID-19 pandemic. Front Immunol. 2024;15:1363572

24. Taieb A, Nassim BHS, Asma G, Jabeur M, Ghada S, Asma BA. The Growing Understanding of the Pituitary Implication in the Pathogenesis of Long COVID-19 Syndrome: A Narrative Review. Adv Respir Med. 2024;92:96-109

25. Dutton CM, Joba W, Spitzweg C, Heufelder AE, Bahn RS. Thyrotropin receptor expression in adrenal, kidney, and thymus. Thyroid. 1997;7:879-84

26. Keskin H, Cadirci K, Gungor K, Karaaslan T, Usta T, Ozkeskin A. et al. Association between TSH Values and GFR Levels in Euthyroid Cases with Metabolic Syndrome. Int J Endocrinol. 2021;2021:8891972

27. Vargas F, Rodríguez-Gómez I, Vargas-Tendero P, Jimenez E, Montiel M. The renin-angiotensin system in thyroid disorders and its role in cardiovascular and renal manifestations. J Endocrinol. 2012;213:25-36

28. Farhadi SAS, Dizaye KF. Aliskiren, Fosinopril, and Their Outcome on Renin-Angiotensin-Aldosterone System (RAAS) in Rats with Thyroid Dysfunction. Int J Endocrinol. 2019;2019:5960563

29. Iglesias P, Bajo MA, Selgas R, Díez JJ. Thyroid dysfunction and kidney disease: An update. Reviews in Endocrine and Metabolic Disorders. 2017;18:131-44

30. Iglesias P, Acosta M, Sánchez R, Fernández-Reyes MJ, Mon C, Díez JJ. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function. Clinical Endocrinology. 2005;63:66-72

31. Vargas F, Moreno JM, Rodríguez-Gómez I, Wangensteen R, Osuna A, Alvarez-Guerra M. et al. Vascular and renal function in experimental thyroid disorders. European Journal of Endocrinology. 2006;154:197-212

32. Katz AI, Lindheimer MD. Renal sodium- and potassium-activated adenosine triphosphatase and sodium reabsorption in the hypothyroid rat. J Clin Invest. 1973;52:796-804

33. Facchiano A, Facchiano F, Facchiano A. An investigation into the molecular basis of cancer comorbidities in coronavirus infection. FEBS Open Bio. 2020;10:2363-74

34. Lui DTW, Lee CH, Chow WS, Lee ACH, Tam AR, Fong CHY. et al. Thyroid Dysfunction in Relation to Immune Profile, Disease Status, and Outcome in 191 Patients with COVID-19. J Clin Endocrinol Metab. 2021;106:e926-e35

35. Ayari H, Legedz L, Cerutti C, Lantelme P, Feugier P, Gustin M-P. et al. Mutual amplification of corticosteroids and angiotensin systems in human vascular smooth muscle cells and carotid atheroma. J Mol Med (Berl). 2014;92:1201-8

36. Daimon M, Kamba A, Murakami H, Takahashi K, Otaka H, Makita K. et al. Association Between Pituitary-Adrenal Axis Dominance Over the Renin-Angiotensin-Aldosterone System and Hypertension. J Clin Endocrinol Metab. 2016;101:889-97

37. Hunter RW, Ivy JR, Bailey MA. Glucocorticoids and renal Na+ transport: implications for hypertension and salt sensitivity. J Physiol. 2014;592:1731-44

38. Frindt G, Palmer LG. Regulation of epithelial Na+ channels by adrenal steroids: mineralocorticoid and glucocorticoid effects. Am J Physiol Renal Physiol. 2012;302:F20-F6

39. Lorenz JN, Loreaux EL, Dostanic-Larson I, Lasko V, Schnetzer JR, Paul RJ. et al. ACTH-induced hypertension is dependent on the ouabain-binding site of the alpha2-Na+-K+-ATPase subunit. Am J Physiol Heart Circ Physiol. 2008;295:H273-H80

40. Gideon A, Sauter C, Fieres J, Berger T, Renner B, Wirtz PH. Kinetics and Interrelations of the Renin Aldosterone Response to Acute Psychosocial Stress: A Neglected Stress System. J Clin Endocrinol Metab. 2020;105:e762-e73

41. Bollag WB. Regulation of aldosterone synthesis and secretion. Compr Physiol. 2014;4:1017-55

42. El Ghorayeb N, Bourdeau I, Lacroix A. Role of ACTH and Other Hormones in the Regulation of Aldosterone Production in Primary Aldosteronism. Front Endocrinol (Lausanne). 2016;7:72

43. Oelkers W, Köhler A, Belkien L, Fuchs-Hammoser R, Maiga M, Scherer B. et al. Studies on the mechanism by which ACTH stimulates renin activity and angiotensin II formation in man. Acta Endocrinol (Copenh). 1982;100:573-80

44. Gideon A, Sauter C, Pruessner JC, Farine DR, Wirtz PH. Determinants and Mechanisms of the Renin-Aldosterone Stress Response. Psychosom Med. 2022;84:50-63

45. Mao Y, Xu B, Guan W, Xu D, Li F, Ren R. et al. The Adrenal Cortex, an Underestimated Site of SARS-CoV-2 Infection. Front Endocrinol (Lausanne). 2020;11:593179

46. Clarke SA, Phylactou M, Patel B, Mills EG, Muzi B, Izzi-Engbeaya C. et al. Letter to the editor of clinical endocrinology: Assessment of adrenal function in patients who survive COVID-19. Clinical Endocrinology. 2023;98:270-2

47. Vakhshoori M, Heidarpour M, Bondariyan N, Sadeghpour N, Mousavi Z. Adrenal Insufficiency in Coronavirus Disease 2019 (COVID-19)-Infected Patients without Preexisting Adrenal Diseases: A Systematic Literature Review. Int J Endocrinol. 2021;2021:2271514

48. Yu Z, Yang J, Huang W-J, Zhang T, Li X-M, Zhao W. et al. Follicle stimulating hormone promotes production of renin through its receptor in juxtaglomerular cells of kidney. Diabetol Metab Syndr. 2022;14:65

49. Wiegel RE, Karsten MJH, Reijnders IF, van Rossem L, Willemsen SP, Mulders AGMGJ. et al. Corpus luteum number and the maternal renin-angiotensin-aldosterone system as determinants of utero-placental (vascular) development: the Rotterdam Periconceptional Cohort. Reproductive Biology and Endocrinology. 2021;19:164

50. Gersh FL, O'Keefe JH, Lavie CJ, Henry BM. The Renin-Angiotensin-Aldosterone System in Postmenopausal Women: The Promise of Hormone Therapy. Mayo Clin Proc. 2021;96:3130-41

51. Xue B, Johnson AK, Hay M. Sex differences in angiotensin II- and aldosterone-induced hypertension: the central protective effects of estrogen. American Journal of Physiology Regulatory, Integrative and Comparative Physiology. 2013;305:R459-R63

52. Xiang X, Xie L, Lin J, Pare R, Huang G, Huang J. et al. Estrogen receptor alpha mediates 17β-estradiol, up-regulates autophagy and alleviates hydrogen peroxide-induced vascular senescence. Biogerontology. 2023;24(5):783-799

53. Zhu Y, Bian Z, Lu P, Karas RH, Bao L, Cox D. et al. Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science. 2002;295:505-8

54. Rossi GP, Caroccia B, Seccia TM. Role of estrogen receptors in modulating aldosterone biosynthesis and blood pressure. Steroids. 2019;152:108486

55. White MC, Fleeman R, Arnold AC. Sex differences in the metabolic effects of the renin-angiotensin system. Biol Sex Differ. 2019;10:31

56. Khan N. Possible protective role of 17β-estradiol against COVID-19. J Allergy Infect Dis. 2020;1:38-48

57. Sund M, Fonseca-Rodríguez O, Josefsson A, Welen K, Fors Connolly A-M. Association between pharmaceutical modulation of oestrogen in postmenopausal women in Sweden and death due to COVID-19: a cohort study. BMJ Open. 2022;12:e053032

58. Seeland U, Coluzzi F, Simmaco M, Mura C, Bourne PE, Heiland M. et al. Evidence for treatment with estradiol for women with SARS-CoV-2 infection. BMC Med. 2020;18:369

59. Shi J, Wei D, Wang L, Xu Q, Wang J, Ma C. et al. Serum Progesterone is Negatively Associated with Hypertension and Blood Pressure Indicators Among Men and Postmenopausal Women. Horm Metab Res. 2023;55:273-83

60. Kristiansson P, Wang JX. Reproductive hormones and blood pressure during pregnancy. Human Reproduction. 2001;16:13-7

61. Perusquía M, Hernández R, Morales MA, Campos MG, Villalón CM. Role of endothelium in the vasodilating effect of progestins and androgens on the rat thoracic aorta. Gen Pharmacol. 1996;27:181-5

62. Sundsfjord JA, Aakvaag A. Variations in plasma aldosterone and plasma renin activity throughout the menstrual cycle, with special reference to the pre-ovulatory period. Acta Endocrinol (Copenh). 1973;73:499-508

63. Hirshoren N, Tzoran I, Makrienko I, Edoute Y, Plawner MM, Itskovitz-Eldor J. et al. Menstrual cycle effects on the neurohumoral and autonomic nervous systems regulating the cardiovascular system. J Clin Endocrinol Metab. 2002;87:1569-75

64. Orshal JM, Khalil RA. Gender, sex hormones, and vascular tone. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology. 2004;286:R233-R49

65. Stachenfeld NS, Keefe DL, Taylor HS. Responses to a saline load in gonadotropin-releasing hormone antagonist-pretreated premenopausal women receiving progesterone or estradiol-progesterone therapy. J Clin Endocrinol Metab. 2005;90:386-94

66. Stachenfeld NS, Taylor HS. Progesterone increases plasma volume independent of estradiol. J Appl Physiol (1985). 2005;98:1991-7

67. Szmuilowicz ED, Adler GK, Williams JS, Green DE, Yao TM, Hopkins PN. et al. Relationship between aldosterone and progesterone in the human menstrual cycle. J Clin Endocrinol Metab. 2006;91:3981-7

68. Ghandehari S, Matusov Y, Pepkowitz S, Stein D, Kaderi T, Narayanan D. et al. Progesterone in Addition to Standard of Care vs Standard of Care Alone in the Treatment of Men Hospitalized with Moderate to Severe COVID-19: A Randomized, Controlled Pilot Trial. Chest. 2021;160:74-84

69. Mabillard H, Sayer JA. Electrolyte Disturbances in SARS-CoV-2 Infection. F1000Res. 2020;9:587

70. Elabida B, Edwards A, Salhi A, Azroyan A, Fodstad H, Meneton P. et al. Chronic potassium depletion increases adrenal progesterone production that is necessary for efficient renal retention of potassium. Kidney Int. 2011;80:256-62

71. Brandi ML. Are sex hormones promising candidates to explain sex disparities in the COVID-19 pandemic? Rev Endocr Metab Disord. 2022;23:171-83

72. Shihan M, Bulldan A, Scheiner-Bobis G. Non-classical testosterone signaling is mediated by a G-protein-coupled receptor interacting with Gnα11. Biochim Biophys Acta. 2014;1843:1172-81

73. Te Riet L, van Esch JHM, Roks AJM, van den Meiracker AH, Danser AHJ. Hypertension: renin-angiotensin-aldosterone system alterations. Circ Res. 2015;116:960-75

74. Mishra JS, More AS, Gopalakrishnan K, Kumar S. Testosterone plays a permissive role in angiotensin II-induced hypertension and cardiac hypertrophy in male rats. Biol Reprod. 2019;100:139-48

75. Song J, Kost CK, Martin DS. Androgens augment renal vascular responses to ANG II in New Zealand genetically hypertensive rats. American Journal of Physiology Regulatory, Integrative and Comparative Physiology. 2006;290:R1608-R15

76. Kienitz T, Quinkler M. Testosterone and blood pressure regulation. Kidney Blood Press Res. 2008;31:71-9

77. Yanes LL, Romero DG, Moulana M, Lima R, Davis DD, Zhang H. et al. Cardiovascular-renal and metabolic characterization of a rat model of polycystic ovary syndrome. Gend Med. 2011;8:103-15

78. Reckelhoff JF. Androgens and Blood Pressure Control: Sex Differences and Mechanisms. Mayo Clin Proc. 2019;94:536-43

79. Dalmasso C, Patil CN, Yanes Cardozo LL, Romero DG, Maranon RO. Cardiovascular and Metabolic Consequences of Testosterone Supplements in Young and Old Male Spontaneously Hypertensive Rats: Implications for Testosterone Supplements in Men. J Am Heart Assoc. 2017;6:e007074

80. Douglas GC, O'Bryan MK, Hedger MP, Lee DKL, Yarski MA, Smith AI. et al. The Novel Angiotensin-Converting Enzyme (ACE) Homolog, ACE2, Is Selectively Expressed by Adult Leydig Cells of the Testis. Endocrinology. 2004;145:4703-11

81. Hackett G, Kirby M. Testosterone deficiency in men infected with COVID-19. Trends in Urology & Men's Health. 2020;11:7-10

82. Barnes BJ, Adrover JM, Baxter-Stoltzfus A, Borczuk A, Cools-Lartigue J, Crawford JM. et al. Targeting potential drivers of COVID-19: Neutrophil extracellular traps. J Exp Med. 2020;217:e20200652

83. Lanser L, Burkert FR, Thommes L, Egger A, Hoermann G, Kaser S. et al. Testosterone Deficiency Is a Risk Factor for Severe COVID-19. Front Endocrinol (Lausanne). 2021;12:694083

84. Rastrelli G, Di Stasi V, Inglese F, Beccaria M, Garuti M, Di Costanzo D. et al. Low testosterone levels predict clinical adverse outcomes in SARS-CoV-2 pneumonia patients. Andrology. 2021;9:88-98

85. Pozzilli P, Lenzi A. Commentary: Testosterone, a key hormone in the context of COVID-19 pandemic. Metabolism. 2020;108:154252

86. Wambier CG, Goren A. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is likely to be androgen mediated. J Am Acad Dermatol. 2020;83:308-9

87. Bravaccini S, Fonzi E, Tebaldi M, Angeli D, Martinelli G, Nicolini F. et al. Estrogen and Androgen Receptor Inhibitors: Unexpected Allies in the Fight Against COVID-19. Cell Transplant. 2021;30:963689721991477

88. Montopoli M, Zumerle S, Vettor R, Rugge M, Zorzi M, Catapano CV. et al. Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532). Ann Oncol. 2020;31:1040-5

89. Melmed S. Pathogenesis and Diagnosis of Growth Hormone Deficiency in Adults. N Engl J Med. 2019;380:2551-62

90. Kopchick JJ, Basu R, Berryman DE, Jorgensen JOL, Johannsson G, Puri V. Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer. Nature Reviews Endocrinology. 2022;18:558-73

91. Tidblad A. The history, physiology and treatment safety of growth hormone. Acta Paediatrica. 2022;111:215-24

92. Møller J. Effects of growth hormone on fluid homeostasis. Clinical and experimental aspects. Growth Horm IGF Res. 2003;13:55-74

93. de Boer H, Blok GJ, Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995;16:63-86

94. Boguszewski MCS. Growth hormone deficiency and replacement in children. Rev Endocr Metab Disord. 2021;22:101-8

95. Ilatovskaya DV, Levchenko V, Brands MW, Pavlov TS, Staruschenko A. Cross-talk between insulin and IGF-1 receptors in the cortical collecting duct principal cells: implication for ENaC-mediated Na+ reabsorption. Am J Physiol Renal Physiol. 2015;308:F713-F9

96. Debonneville C, Flores SY, Kamynina E, Plant PJ, Tauxe C, Thomas MA. et al. Phosphorylation of Nedd4-2 by Sgk1 regulates epithelial Na(+) channel cell surface expression. EMBO J. 2001;20:7052-9

97. Kamenický P, Mazziotti G, Lombès M, Giustina A, Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev. 2014;35:234-81

98. Giani JF, Miquet JG, Muñoz MC, Burghi V, Toblli JE, Masternak MM. et al. Upregulation of the angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas receptor axis in the heart and the kidney of growth hormone receptor knock-out mice. Growth Horm IGF Res. 2012;22:224-33

99. Muñoz MC, Burghi V, Miquet JG, Giani JF, Banegas RD, Toblli JE. et al. Downregulation of the ACE2/Ang-(1-7)/Mas axis in transgenic mice overexpressing GH. J Endocrinol. 2014;221:215-27

100. Brill G, Manor I, Bril Paroz R, Ashkenazi S, Cohen S, Golan-Cohen A. et al. The Association between Somatotropin Therapy and the Risk of SARS-CoV-2 Infection in Children with Short Stature: A Population-Based Cross-Sectional Study. Children (Basel). 2022;9:1844

101. Li X, Zhou Y, Yuan S, Zhou X, Wang L, Sun J. et al. Genetically predicted high IGF-1 levels showed protective effects on COVID-19 susceptibility and hospitalization: a Mendelian randomisation study with data from 60 studies across 25 countries. Elife. 2022;11:e79720

102. Fan X, Yin C, Wang J, Yang M, Ma H, Jin G. et al. Pre-diagnostic circulating concentrations of insulin-like growth factor-1 and risk of COVID-19 mortality: results from UK Biobank. Eur J Epidemiol. 2021;36:311-8

103. Gao C, Cai Y, Zhang K, Zhou L, Zhang Y, Zhang X. et al. Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. Eur Heart J. 2020;41:2058-66

104. Elkarow MH, Hamdy A. A Suggested Role of Human Growth Hormone in Control of the COVID-19 Pandemic. Front Endocrinol (Lausanne). 2020;11:569633

105. Ball SG. Vasopressin and disorders of water balance: the physiology and pathophysiology of vasopressin. Ann Clin Biochem. 2007;44:417-31

106. Aoyagi T, Birumachi J-i, Hiroyama M, Fujiwara Y, Sanbe A, Yamauchi J. et al. Alteration of glucose homeostasis in V1a vasopressin receptor-deficient mice. Endocrinology. 2007;148:2075-84

107. Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K. et al. Hypermetabolism of Fat in V1a Vasopressin Receptor Knockout Mice. Molecular Endocrinology. 2007;21:247-58

108. Koshimizu T-a, Nakamura K, Egashira N, Hiroyama M, Nonoguchi H, Tanoue A. Vasopressin V1a and V1b receptors: from molecules to physiological systems. Physiol Rev. 2012;92:1813-64

109. Qian Q. Salt, water and nephron: Mechanisms of action and link to hypertension and chronic kidney disease. Nephrology (Carlton). 2018;23(Suppl 4):44-9

110. Kellenberger S, Schild L. Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol Rev. 2002;82:735-67

111. Izumi Y, Nakayama Y, Mori T, Miyazaki H, Inoue H, Kohda Y. et al. Downregulation of vasopressin V2 receptor promoter activity via V1a receptor pathway. Am J Physiol Renal Physiol. 2007;292:F1418-F26

112. Terada Y, Tomita K, Nonoguchi H, Yang T, Marumo F. Different localization and regulation of two types of vasopressin receptor messenger RNA in microdissected rat nephron segments using reverse transcription polymerase chain reaction. J Clin Invest. 1993;92:2339-45

113. Yacoub R, Campbell KN. Inhibition of RAS in diabetic nephropathy. Int J Nephrol Renovasc Dis. 2015;8:29-40

114. Aoyagi T, Izumi Y, Hiroyama M, Matsuzaki T, Yasuoka Y, Sanbe A. et al. Vasopressin regulates the renin-angiotensin-aldosterone system via V1a receptors in macula densa cells. Am J Physiol Renal Physiol. 2008;295:F100-F7

115. Gonzalez AA, Cifuentes-Araneda F, Ibaceta-Gonzalez C, Gonzalez-Vergara A, Zamora L, Henriquez R. et al. Vasopressin/V2 receptor stimulates renin synthesis in the collecting duct. Am J Physiol Renal Physiol. 2016;310:F284-F93

116. Wang Y, Chen B, Li Y, Zhang L, Wang Y, Yang S. et al. The use of renin-angiotensin-aldosterone system (RAAS) inhibitors is associated with a lower risk of mortality in hypertensive COVID-19 patients: A systematic review and meta-analysis. J Med Virol. 2021;93:1370-7

117. Scroggins SM, Sharp LE, Lund JM, Devor EJ, Warrier A, Hamilton WS. et al. Abstract P132: Differential and Sex Dependent Expression of Vasopressin Receptors by B Cells, NK Cells, and Dendritic Cells. Hypertension. 2019;74:AP132-AP

118. Yousaf Z, Al-Shokri SD, Al-Soub H, Mohamed MFH. COVID-19-associated SIADH: a clue in the times of pandemic!. American Journal of Physiology Endocrinology and Metabolism. 2020;318:E882-E5

119. Hu W, Lv X, Li C, Xu Y, Qi Y, Zhang Z. et al. Disorders of sodium balance and its clinical implications in COVID-19 patients: a multicenter retrospective study. Intern Emerg Med. 2021;16:853-62

120. Tzoulis P, Waung JA, Bagkeris E, Hussein Z, Biddanda A, Cousins J. et al. Dysnatremia is a Predictor for Morbidity and Mortality in Hospitalized Patients with COVID-19. J Clin Endocrinol Metab. 2021;106:1637-48

121. Friedman B, Cirulli J. Hyponatremia in critical care patients: frequency, outcome, characteristics, and treatment with the vasopressin V2-receptor antagonist tolvaptan. J Crit Care. 2013;28:219.e1-12

122. Al-Kuraishy HM, Al-Gareeb AI, Faidah H, Al-Maiahy TJ, Cruz-Martins N, Batiha GE-S. The Looming Effects of Estrogen in Covid-19: A Rocky Rollout. Front Nutr. 2021;8:649128

123. Wang G, Deng J, Li J, Wu C, Dong H, Wu S. et al. The Role of High-Density Lipoprotein in COVID-19. Front Pharmacol. 2021;12:720283

124. Ding T, Zhang J, Wang T, Cui P, Chen Z, Jiang J. et al. Potential Influence of Menstrual Status and Sex Hormones on Female Severe Acute Respiratory Syndrome Coronavirus 2 Infection: A Cross-sectional Multicenter Study in Wuhan, China. Clin Infect Dis. 2021;72:e240-e8

125. Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. Biol Sex Differ. 2017;8:33

126. Arnold CG, Libby A, Vest A, Hopkinson A, Monte AA. Immune mechanisms associated with sex-based differences in severe COVID-19 clinical outcomes. Biol Sex Differ. 2022;13:7

127. Li F, Boon ACM, Michelson AP, Foraker RE, Zhan M, Payne PRO. Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19. Sci Rep. 2022;12:9462

128. Averyanova M, Vishnyakova P, Yureneva S, Yakushevskaya O, Fatkhudinov T, Elchaninov A. et al. Sex hormones and immune system: Menopausal hormone therapy in the context of COVID-19 pandemic. Front Immunol. 2022;13:928171

129. Karkhanei B, Talebi Ghane E, Mehri F. Evaluation of oxidative stress level: total antioxidant capacity, total oxidant status and glutathione activity in patients with COVID-19. New Microbes New Infect. 2021;42:100897

130. Breithaupt-Faloppa AC, Correia CdJ, Prado CM, Stilhano RS, Ureshino RP, Moreira LFP. 17β-Estradiol, a potential ally to alleviate SARS-CoV-2 infection. Clinics (Sao Paulo). 2020;75:e1980

131. Elfiky AA. Natural products may interfere with SARS-CoV-2 attachment to the host cell. J Biomol Struct Dyn. 2021;39:3194-203

132. LaVasseur C, Mathews R, Wang JSH, Martens K, McMurry HS, Peress S. et al. Estrogen-based hormonal therapy and the risk of thrombosis in COVID-19 patients. Eur J Haematol. 2023;111(5):678-686

133. Ramanadhan S, Hansen K, Henderson JT, Cohen MA, Paynter R, Edelman A. Risk of thromboembolism in patients with COVID-19 who are using hormonal contraception. Cochrane Database Syst Rev. 2023;5:CD014908

134. Ardestani A, Azizi Z. Targeting glucose metabolism for treatment of COVID-19. Signal Transduct Target Ther. 2021;6:112

135. He B, Wang J, Wang Y, Zhao J, Huang J, Tian Y. et al. The Metabolic Changes and Immune Profiles in Patients With COVID-19. Front Immunol. 2020;11:2075

136. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E. et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med. 2020;48:e440-e69

137. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:626-38

138. Jakovac H. Sex differences in COVID-19 course and outcome: progesterone should not be neglected. J Appl Physiol (1985). 2020;129:1007-8

139. Khanmohammadi S, Rezaei N. Role of Toll-like receptors in the pathogenesis of COVID-19. J Med Virol. 2021;93:2735-9

140. Chen Q, Qi X, Zhang W, Zhang Y, Bi Y, Meng Q. et al. Catalpol Inhibits Macrophage Polarization and Prevents Postmenopausal Atherosclerosis Through Regulating Estrogen Receptor Alpha. Front Pharmacol. 2021;12:655081

141. Wu C, Yang W, Wu X, Zhang T, Zhao Y, Ren W. et al. Clinical Manifestation and Laboratory Characteristics of SARS-CoV-2 Infection in Pregnant Women. Virol Sin. 2020;35:305-10

142. Okpechi SC, Fong JT, Gill SS, Harman JC, Nguyen TH, Chukwurah QC. et al. Global Sex Disparity of COVID-19: A Descriptive Review of Sex Hormones and Consideration for the Potential Therapeutic Use of Hormone Replacement Therapy in Older Adults. Aging Dis. 2021;12:671-83

143. Giotis ES, Cil E, Brooke GN. Use of Antiandrogens as Therapeutic Agents in COVID-19 Patients. Viruses. 2022;14:2728

144. Mauvais-Jarvis F. Do Anti-androgens Have Potential as Therapeutics for COVID-19? Endocrinology. 2021;162:bqab114

145. Salciccia S, Del Giudice F, Eisenberg ML, Mastroianni CM, De Berardinis E, Ricciuti GP. et al. Testosterone target therapy: focus on immune response, controversies and clinical implications in patients with COVID-19 infection. Therapeutic Advances in Endocrinology and Metabolism. 2021;12:20420188211010105

146. Walker RF, Zakai NA, MacLehose RF, Cowan LT, Adam TJ, Alonso A. et al. Association of Testosterone Therapy with Risk of Venous Thromboembolism Among Men with and Without Hypogonadism. JAMA Intern Med. 2020;180:190-7

147. Becker RC. COVID-19 update: Covid-19-associated coagulopathy. J Thromb Thrombolysis. 2020;50:54-67

148. Cadegiani FA, McCoy J, Gustavo Wambier C, Vaño-Galván S, Shapiro J, Tosti A. et al. Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial. Cureus. 2021;13:e13492

149. Cadegiani FA, Zimerman RA, Fonseca DN, Correia MN, Muller MP, Bet DL. et al. Final Results of a Randomized, Placebo-Controlled, Two-Arm, Parallel Clinical Trial of Proxalutamide for Hospitalized COVID-19 Patients: A Multiregional, Joint Analysis of the Proxa-Rescue AndroCoV Trial. Cureus. 2021;13:e20691

150. Welén K, Rosendal E, Gisslén M, Lenman A, Freyhult E, Fonseca-Rodríguez O. et al. A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In vitro Data. Eur Urol. 2022;81:285-93

Author contact

Corresponding authors: Yunfeng Liu, email address: nectarliucom, Department of Endocrinology, First Hospital of Shanxi Medical University, Taiyuan, 030001, China. Yi Zhang, email address: yizhang313com, Department of Pharmacology, Shanxi Medical University, Taiyuan, 030001, China.

Citation styles

©2025 Ivyspring International Publisher. Terms of use